| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$135.2M | ROE | −41.27% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies to counter resistance mechanisms in cancers in the United States. Its candidates include enozertinib, a brain-penetrant inhibitor targeting EGFR and HER2 exon 20 mutations in a Phase 1b study, and rinzimetostat, an allosteric PRC2 inhibitor for prostate cancer in a Phase 1b study. The company has clinical collaborations with Bayer.
| Market Cap | $1.23B | Trading Days | 1359 |
| 52W High | 14.93 |
| 52W Low | 7.23 |
| % Off High | −20.23% |
| YTD | 45.60% | 1Y | 6.53% |
| 3Y | 44.36% | 5Y | −33.43% |
| Since incept. (ann.) | −18.32% |
| Ann. Volatility (1Y) | 82.25% | Ann. Volatility (3Y) | 80.06% |
| Sharpe (1Y) | 0.52 | Sharpe (3Y) | 0.58 |
| Max Drawdown (1Y) | −48.13% | Max Drawdown (3Y) | −73.46% |
| Beta (3Y, vs SPY) | 1.95 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OPK | OPKO HEALTH, INC. | $1.23B | — |
| AVLN | Avalyn Pharma Inc. | $1.22B | — |
| ARDX | ARDELYX, INC. | $1.26B | — |
| MNKD | MANNKIND CORP | $1.21B | 195.5 |
| ETON | Eton Pharmaceuticals, Inc. | $1.28B | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.16B | 20.8 |
| WVE | Wave Life Sciences Ltd. | $1.13B | — |
| SDGR | Schrodinger, Inc. | $1.12B | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.12B | — |
| MLTX | MoonLake Immunotherapeutics | $1.38B | — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | — |
| SVRA | Savara Inc | $1.09B | — |
